ComFit Europe Ltd. https://comfiteurope.eu Tue, 16 Sep 2025 13:46:04 +0000 hu hourly 1 https://wordpress.org/?v=4.7.38 We won the Visa She’s Next 2025 award https://comfiteurope.eu/winning-visa-shes-next-2025-award/ Tue, 08 Jul 2025 09:32:22 +0000 https://comfiteurope.eu/?p=16853 Proud to share that we are one of the winners of Visa She’s Next 2025. This program recognizes women-led businesses that have already proven themselves — and are now preparing for their next leap. Applicants had to present their vision in a live pitch session...

The post We won the Visa She’s Next 2025 award appeared first on ComFit Europe Ltd..

]]>
Proud to share that we are one of the winners of Visa She’s Next 2025.

This program recognizes women-led businesses that have already proven themselves — and are now preparing for their next leap. Applicants had to present their vision in a live pitch session before a 10-member jury. It was not just a competition, but a process of reflection and growth.

We are truly thankful to Impact Hub and Visa for their outstanding work and the inspiration and support they offered throughout the process.

This award is not only a recognition — it’s also momentum. It remind us that while we can make decisions and lead progress on our own, the biggest shifts often come when we let others challenge, question, and expand our thinking.

Visa’s post about the program:
https://www.visa.hu/a-visa-rol/visa-szerkesztoseg/press-releases.3390167.html

The post We won the Visa She’s Next 2025 award appeared first on ComFit Europe Ltd..

]]>
EMA say: day zero starts at receipt of physical/hard copy local journals! Implications: contradictions with GVP, low impact on patient safety, higher costs for MAH https://comfiteurope.eu/ema-say-day-zero-starts-at-receipt-of-hard-copies/ Wed, 08 Feb 2023 15:18:49 +0000 https://comfiteurope.eu/?p=16714 EMA posted the following interpretation of the Pharmacovigilance Inspectors Working Group in January 2023: “For ICSRs, medical literature containing the minimum criteria, the clock starts (day zero) on the day when the physical/hard copy local journal is received by the organisation/Marketing authorisation holder/Applicant, and this...

The post EMA say: day zero starts at receipt of physical/hard copy local journals! Implications: contradictions with GVP, low impact on patient safety, higher costs for MAH appeared first on ComFit Europe Ltd..

]]>
EMA posted the following interpretation of the Pharmacovigilance Inspectors Working Group in January 2023:
“For ICSRs, medical literature containing the minimum criteria, the clock starts (day zero) on the day when
the physical/hard copy local journal is received by the organisation/Marketing authorisation holder/Applicant,
and this should be considered equal to performing a literature search in an electronic database.”
https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/compliance/coordination-pharmacovigilance-inspections

 

At present the general understanding is that day zero starts when the assessment of an article comes to a result. And the relevance and challenge of the topic is that day zero tends to be equal a 24-hour constraint in literature monitoring at most subsidiaries of MAHs:
This is what EMA suggests:
It is possible to live up to a 24-hour processing of hard copies starting with receipt of the copy, but due to the cut in time of the present practice and unpredictability of the exact receipt as well as the unpredictable number of articles in the copies, this interpretation implies to grow considerably the resources for monitoring. What’s the benefit from the point of view of patient safety and who will pay for that?

 

I. The interpretation of EMA does not seem to be in harmony with GVP. Here are the arguments:
A. Receipt time of the physical copies cannot be considered as the awareness of the minimum criteria due to the time span between the two points
Awareness supposes that all articles were read, they were matched with the search terms of the given MAH, assessment was carried out and evaluation was made about the presence of an ICSR (or relevant information for therapeutic area about the active substance). The process that leads to the awareness requires time. Receiving a journal can only be the starting point of the process that can result in awareness. There is a time span between the receipt of copies and the end to the assessment, therefore the time of their receipt cannot be the same as the awareness of the minimum criteria.
B. EMA equal search in physical copy local journals to search in an electronic database, which is not right
This approach disregards that running a search in an electronic database brings targeted result while at hard/physical copies you have to spend time reading through a journal to get to the level of data from where the electronic search starts. It is a big difference between the two ways that in electronic database search you only occupy with articles that have relevance to your requirements. In hard/physical copies, first you have to find the articles related to your portfolio. What is seconds in an electronic database, it may take days in physical/hard copies, just think about an abstract book with 600 abstracts.
Another issue is what we mean by receipt of the journal. With hard/physical copies, the receipt of the copies at an organization usually means that the copy has arrived at the reception desk. It goes through administration before getting into the hands of the responsible person trained to assess articles. Please also consider the impact of a general tendency: what if the responsible person works in home office. All in all, at hard copies, there is a time lap compared to search in electronic database. Therefore, search in physical copies cannot be taken to be equal to monitoring in an electronic database from the point of view of time.

 

II. Low impact on patient safety and higher costs for MAH
It is hard, but possible to build a literature monitoring process that starts with the receipt of physical copies and meet 24-hour timeline in journals’ processing. The question is rather whether the risk-benefit assessment is favorable to aim at such a target.
C. The unpredictable arrival date of hard copy journals would mean big stand-by resources to keep
Hard copies can arrive at the organisations with postal service. Upon our 15-year-old experience in literature monitoring, the packaging and delivery of quarterly and monthly print copies mean +/-3 days compared to the date set by the publishing house. If you cannot know which day your organization will receive the medical journal exactly and you have a 24 hour processing constraint, you have to keep stand-by resources for the days when it may come. Having a group of trained, professionals on stand-by costs a lot, especially if you think of abstract books.
D. Abstract books – how to manage reasonably their ad hoc publishing and immense number of abstracts in 24 hours?
Generally speaking, a medical journal contains about 10 articles, they come more or less regularly and the article number is predictable by journal. You can calculate well how much resource you need for processing them. Abstract books can have 400 abstracts in one issue, they are rare to come and rather unpredictable in their arrival and their number of abstracts. 10 articles opposite to 400 abstracts in 24 hours. It is not the same resource. If you have to meet 24 hours with abstract books, too, you should keep significantly larger resources on stand-by all through the year.
E. Three-month old ICSRs in literature at least. Is a 24-hour deadline favourable from risk-benefit assessment?
A case in local literature or reference databases is at least three-month old when we are going to read about it in an article. 80% of medical journals are quarterly journals – 3 months to get to the reader. The 24-hour processing deadline does not seem to be reasonable while the original article drafts with the cases are waiting for months before publishing. And the delay starts with the doctors who are obliged to report cases, but they do not do it…..

 

III. Further comments:
F. How easier compliance with rules would be if EMA or GVP set at least the basics
–  No less frequently than once a week” (VI.B.1.1.2. Literature reports)– why not saying simply once a week? What is the added value of no less frequently?
–  “Scientific and medical publications” (VI.B.1.1.2. Literature reports) What is the definition of the terms – scientific and medical? How to interpret the conjunction and? Exclusion or inclusion? Why not medicine agencies take the role to publish the list of journals for monitoring? The medicine agency of Croatia and Hungary managed it.
G. GVP does not make a distinction of requirements for hard or electronic copies
Neither in this VI.B.7. Submission of individual case safety reports (ICSRs) nor in VI.App.2.7. Day zero, are there any references to differences as for physical/hard or electronic copies. These sections that EMA referred to as background of the interpretation speak about how to understand the terms day zero and ICSRs, no matter what the delivery format of the journal.
H.Reference databases contain local journals!
All journals have a publishing house, publishing houses have a headquarter which has an address in a country. In the end, all journals related to a country and can be considered local journals. Reference databases contain local journals. EMA’s interpretation speaks about the physical/hard copy local journal. However, the stricter deadline suggested in the interpretation can be the challenge of reference databases, too if they monitor journals that only deliver in physical/hard copies.

 

The post EMA say: day zero starts at receipt of physical/hard copy local journals! Implications: contradictions with GVP, low impact on patient safety, higher costs for MAH appeared first on ComFit Europe Ltd..

]]>
AUDIT LEARNINGS – Training of personnel involved in the literature reviewing process https://comfiteurope.eu/audit-learnings-training-personnel-involved-literature-reviewing-process/ Tue, 27 Nov 2018 16:32:19 +0000 https://comfiteurope.eu/?p=16596 At ComFit, we have been collecting the questions of audits and quality checks for years and turn them into sources of further developments as well as to make them a part of a check-list for the next milestone. We have decided to write a summary...

The post AUDIT LEARNINGS – Training of personnel involved in the literature reviewing process appeared first on ComFit Europe Ltd..

]]>
At ComFit, we have been collecting the questions of audits and quality checks for years and turn them into sources of further developments as well as to make them a part of a check-list for the next milestone. We have decided to write a summary (travel book) on our experiences. We have started to line our audit questions with the applicable chapter of GVP (tour guide) and to think about the potential challenges in the answers.

The post AUDIT LEARNINGS – Training of personnel involved in the literature reviewing process appeared first on ComFit Europe Ltd..

]]>
AUDIT LEARNINGS – Keeping track of the monitored journal list https://comfiteurope.eu/audit-learnings-keeping-track-monitored-journal-list/ Tue, 13 Nov 2018 16:30:14 +0000 https://comfiteurope.eu/?p=16587 At ComFit, we have been collecting the questions of audits and quality checks for years and turn them into sources of further developments as well as to make them a part of a check-list for the next milestone. We have decided to write a summary...

The post AUDIT LEARNINGS – Keeping track of the monitored journal list appeared first on ComFit Europe Ltd..

]]>
At ComFit, we have been collecting the questions of audits and quality checks for years and turn them into sources of further developments as well as to make them a part of a check-list for the next milestone. We have decided to write a summary (travel book) on our experiences. We have started to line our audit questions with the applicable chapter of GVP (tour guide) and to think about the potential challenges in the answers.

The post AUDIT LEARNINGS – Keeping track of the monitored journal list appeared first on ComFit Europe Ltd..

]]>
7 Questions + 7 Answers = A Brief Guide to an Effective Literature Monitoring System https://comfiteurope.eu/7-questions-7-answers-brief-guide-effective-literature-system/ Tue, 06 Nov 2018 17:24:54 +0000 https://comfiteurope.eu/?p=16579 As we reached the end of our series on questions and GVP references to build and effective literature system, we would like to provide an overview of the topics we touched upon in the last few weeks as a guide to the 7 steps to...

The post 7 Questions + 7 Answers = A Brief Guide to an Effective Literature Monitoring System appeared first on ComFit Europe Ltd..

]]>
As we reached the end of our series on questions and GVP references to build and effective literature system, we would like to provide an overview of the topics we touched upon in the last few weeks as a guide to the 7 steps to be successful in literature monitoring:
Firstly, we posted about WHERE to search for PV data. The common audit question we discussed in relation to that was: What’s your process for duplicate search? Follow the link for more details: https://comfiteurope.eu/literature-search-pv-data/
Second came WHAT to search FOR in literature. The related audit questions discussed were: What safety data are you searching for in literature? and What’s your indexing method? Or search terms? Find out details here: https://comfiteurope.eu/search-literature-terms-pharmacovigilance/
The third step would be to find out WHICH journals are RELEVANT to monitor. Here we answered to What is a “relevant” source? and Why is a journal out or in the monitored list?: https://comfiteurope.eu/journals-relevant-monitor-pharmacovigilance/
Next we looked at HOW to prove WHICH drugs have been monitored in a given period of time, providing strategies how to answer to challenges such as When and how did you communicate it to the service provider? and How can you prove that the service provider started monitoring?: https://comfiteurope.eu/prove-drugs-monitored-given-period-time/
Then we touched upon HOW to DOCUMENT successfully the literature monitoring activities. Here the most important audit questions to answer are What data are backed up? How often is back-up of critical data done?, Are records probably discarded according to retention rules when no longer needed for business, regulatory or other legal purposes?, How do you control access to archives? How is access authorised?, Are back-up servers located at a different location than the working servers? The details here: https://comfiteurope.eu/document-successfully-literature-monitoring-activities/
Strict timing is crucial in pharmacovigilance. Thus, the sixth step is to find out WHEN to carry out literature monitoring. In relation to that at audits one can be usually asked How can you check whether reviewing meets the timelines as outlined in the agreement? Find out our experience here: https://comfiteurope.eu/carry-literature-monitoring/
The last step we discussed was HOW to successfully SEARCH for PV data without missing anything. The challenges you would often face are: How do you make sure that indexes of the database match the Clients’ search terms, so there will be no loss? and How can you make sure that the medicinal products are indeed the ones specified in the agreement? For details go to: https://comfiteurope.eu/successfully-search-pv-data-without-missing-anything/
We believe that being able to answer to these 7 steps and challenges can form the basis of an effective, audit-proof literature monitoring system. Keep following our feed, as we will continue sharing with you our audit learnings and how we have answered well to common audit questions through our practice!

The post 7 Questions + 7 Answers = A Brief Guide to an Effective Literature Monitoring System appeared first on ComFit Europe Ltd..

]]>
HOW do you successfully SEARCH for PV data without missing anything? https://comfiteurope.eu/successfully-search-pv-data-without-missing-anything/ Tue, 30 Oct 2018 16:30:02 +0000 https://comfiteurope.eu/?p=16574 As GVP is clear that there is “no acceptable loss” (VI.App.2.3.4.) regarding the collection of PV data, ensuring the most reliable search strategy to cover ALL possible challenges and being able to justify its methods is crucial for the functioning of a literature monitoring system....

The post HOW do you successfully SEARCH for PV data without missing anything? appeared first on ComFit Europe Ltd..

]]>
As GVP is clear that there is “no acceptable loss” (VI.App.2.3.4.) regarding the collection of PV data, ensuring the most reliable search strategy to cover ALL possible challenges and being able to justify its methods is crucial for the functioning of a literature monitoring system. Monitoring professionals face numerous difficulties while looking for important information – from spelling variations of drugs through language differences in indexing to the “hidden” case information in pictures and diagrams. Thus, can you rely only on search engines to find all relevant terms without a potential loss? If you want to learn ComFit’s answer to these challenges and more, please refer to our answer below.
This post is the seventh and last in a series. We believe that answering basic questions on search in literature such as which drugs, when etc., can guide us in building an effective literature monitoring system in compliance with GVP. We zoomed into seven questions and shared our experience how we have successfully answered them at ComFit. Stay tuned for more interesting literature monitoring information coming soon!
ComFit’s answer to “How to search” challenges

In order to detect all PV relevant information and to manage different variants of terms in articles, our method of literature monitoring combines the knowledge of trained, medical professionals and a validated software with our clients’ requirements.

With our method, there is no need to specify different variants of search terms.

At ComFit, local medical professionals and pharmacists review the articles, because they are outstanding at understanding texts, and they never miss to index e.g. paclitaxel and lack of efficacy, no matter which spelling or terms are used. Their job is to build our literature database according to our standardised method of indexing and they record all substances and drug names from the articles, independently of who are ComFit’s clients. Our reviewers are not involved in searching and reporting to our clients as multiple variations of data are over the capacity of the human brain. It is a software that searches and reports in the indexed content by matching hundreds of search terms of clients with our database.

Our software is taught on our clients’ product portfolio and search terms such as special situations. We integrate their drugs into our product database. This product database is the basis of our reviewers’ indexing. The field of active substances and products are not open fields for reviewers, but they have to select among the terms in the database while indexing articles. The same is true for special situations, we have our database that backs up indexing and in this database we integrate our clients’ search terms.

Our standardisation method ensures you do not need to bother with different variants of your search terms.

To minimise the risk of any mistakes, there are cross checks built in our revieweing process. All articles are processed by three persons concomitantly and a software algorithm compares their decisions. Accordances, discrepancies and the solution to discrepancies are documented by our software.

The post HOW do you successfully SEARCH for PV data without missing anything? appeared first on ComFit Europe Ltd..

]]>
WHEN to carry out literature monitoring https://comfiteurope.eu/carry-literature-monitoring/ Thu, 25 Oct 2018 15:57:31 +0000 https://comfiteurope.eu/?p=16567 One of the most challenging parts of reviewing is proving that the frequency and method of checking whether the literature monitoring activities are meeting the GVP timelines is efficient enough. Not only should you prove that you have covered ALL publications within a certain period...

The post WHEN to carry out literature monitoring appeared first on ComFit Europe Ltd..

]]>
One of the most challenging parts of reviewing is proving that the frequency and method of checking whether the literature monitoring activities are meeting the GVP timelines is efficient enough. Not only should you prove that you have covered ALL publications within a certain period of time without a miss, no matter if they have been published or delivered with delay, earlier or several simultaneously, but be able to provide proper explanation for any inconsistencies in publishing and when and how you have tracked them. If you want to find out more details on those challenges and how we answer to them in our ComFit software, please refer to the schemes we have prepared below:
This post is the sixth in a series. We believe that answering basic questions on search in literature such as which drugs, when etc., can guide us in building an effective literature monitoring system in compliance with GVP. We are going to zoom into seven questions and share our experience how we have successfully answered them at ComFit. Stay tuned!

The post WHEN to carry out literature monitoring appeared first on ComFit Europe Ltd..

]]>
HOW do you DOCUMENT successfully the literature monitoring activities? https://comfiteurope.eu/document-successfully-literature-monitoring-activities/ Wed, 24 Oct 2018 15:30:05 +0000 https://comfiteurope.eu/?p=16562 The GVP dictates that detailed documentation and record keeping for extended period of time is crucial for proving that the literature monitoring process for collecting adverse drug events and special situations is being carried out in a systematic, well structured and reliable manner. A successful...

The post HOW do you DOCUMENT successfully the literature monitoring activities? appeared first on ComFit Europe Ltd..

]]>
The GVP dictates that detailed documentation and record keeping for extended period of time is crucial for proving that the literature monitoring process for collecting adverse drug events and special situations is being carried out in a systematic, well structured and reliable manner. A successful documentation system can easily and clearly answer who, what, when, where and how in regards to the personnel involved and the way of conduct of literature search, as well as to data collection, storing and back-up. If you want to find out how we have effectively covered these points through our ComFit database management system, please refer to the schemes we have prepared below.

This post is the fifth in a series. We believe that answering basic questions on search in literature such as which drugs, when etc., can guide us in building an effective literature monitoring system in compliance with GVP. We are going to zoom into seven questions and share our experience how we have successfully answered them at ComFit. Stay tuned!

The post HOW do you DOCUMENT successfully the literature monitoring activities? appeared first on ComFit Europe Ltd..

]]>
Consultation about the recommended Hungarian local medical literature list (PV Conference by HURAS – 17th Oct 2018) https://comfiteurope.eu/consultation-recommended-hungarian-local-medical-literature-list-pv-conference-huras-17th-oct-2018/ Thu, 18 Oct 2018 14:55:18 +0000 https://comfiteurope.eu/?p=16546 At the conference on 17th October 2018, organized by the Hungarian Regulatory Affairs Society (HURAS), the CEO of ComFit Europe Ltd., Katalin Timár-Horváth gave a presentation on the recommended list of local medical and scientific literature in Hungary. The recommendation list is under updating on...

The post Consultation about the recommended Hungarian local medical literature list (PV Conference by HURAS – 17th Oct 2018) appeared first on ComFit Europe Ltd..

]]>
At the conference on 17th October 2018, organized by the Hungarian Regulatory Affairs Society (HURAS), the CEO of ComFit Europe Ltd., Katalin Timár-Horváth gave a presentation on the recommended list of local medical and scientific literature in Hungary. The recommendation list is under updating on the request of HURAS, by a working group of 6 literature monitoring experts in Hungary, led by Katalin Timár-Horváth.
The aim of the presentation was to reveal to the members of HURAS that forming the list of local medical journals relevant from pharmacovigilance point of view is challenging because there are journals on the threshold of being relevant or not. The literature list revision working group raised several aspects to consider and asked the opinion of PV professionals attending the yearly PV conference of HURAS. A lively dialogue was set off between around 100 pharmacovigilance professionals. The following aspects were raised: Can serious difficulties of certain journal’s procurement be an exclusion aspect? Does unpredictable periodicity matter in the decision to monitor a medical journal or not? Can we exclude journals targeted at doctors which do not have in focus to publish cases, but they publish some from time to time?
After a spirited discussion, a majority, though slight, of the attendees of the pharmacovigilance conference decided not to consider any of these aspects at forming the list of recommended journals except for being targeted at medical professionals. At the end there are 69+38 journals on the list with the purpose of pharmacovigilance.
The recommended list of local medical and scientific literature was born under the guidance of HURAS in 2012 and updated ever since with the participation of the same experts. Uniquely in the region, this recommended list is approved by the Hungarian Medicines Agency.

The post Consultation about the recommended Hungarian local medical literature list (PV Conference by HURAS – 17th Oct 2018) appeared first on ComFit Europe Ltd..

]]>
HOW do you prove WHICH drugs have been monitored in a given period of time? https://comfiteurope.eu/prove-drugs-monitored-given-period-time/ Tue, 16 Oct 2018 15:30:23 +0000 https://comfiteurope.eu/?p=16536 According to GVP “The marketing authorisation holder has an obligation to review… in the period between the submission of the marketing authorisation application and the granting of the marketing authorisation.” (VI.App.2.1.) While the starting date of monitoring of drugs is something pharma companies agree on,...

The post HOW do you prove WHICH drugs have been monitored in a given period of time? appeared first on ComFit Europe Ltd..

]]>
According to GVP “The marketing authorisation holder has an obligation to review… in the period between the submission of the marketing authorisation application and the granting of the marketing authorisation.” (VI.App.2.1.)
While the starting date of monitoring of drugs is something pharma companies agree on, most of them have different interpretation and practices regarding the end date. At audits they must be able to answer how they communicate changes in monitoring periods of drugs to their literature monitoring service provider and prove that the service provider has been following the respective drug in the necessary period of time. If you want to find out how at ComFit we meet all of our clients’ expectations in documenting the monitoring period of each drug in our system with an audit trail, please refer to the schemes we have prepared below.
 
This post is the fourth in a series. We believe that answering basic questions on search in literature such as which drugs, when etc., can guide us in building an effective literature monitoring system in compliance with GVP. We are going to zoom into seven questions and share our experience how we have successfully answered them at ComFit. Stay tuned!

The post HOW do you prove WHICH drugs have been monitored in a given period of time? appeared first on ComFit Europe Ltd..

]]>